Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592579 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00592579 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00592579, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.
Interventions
- DRUG 2-methoxyestradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592579
The ClinicalTrials.gov registry entry for NCT00592579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-methoxyestradiol is the first listed.
NCT00592579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592579 about?
NCT00592579 is a clinical study titled "A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma". The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.
What is the current status of trial NCT00592579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-03. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00592579?
The interventions under investigation include: 2-methoxyestradiol (DRUG).
Who is sponsoring clinical trial NCT00592579?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.